Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.97 USD | +4.82% | +8.18% | +94.44% |
05-14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
05-13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+94.44% | 296M | |
+26.01% | 49.18B | |
+0.79% | 42.11B | |
+50.07% | 40.37B | |
-5.26% | 28.85B | |
+13.50% | 26.09B | |
-21.92% | 18.71B | |
+8.45% | 13.26B | |
+31.95% | 12.32B | |
+0.39% | 11.99B |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- BofA Securities Upgrades Inovio Pharmaceuticals to Neutral From Underperform, Adjusts Price Target to $10 From $8